Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

HCV, Interferon Therapy Response, Direct Acting Antiviral Therapy Revolution and Pakistan: Future Perspectives

  • Raza, Hamid (Department of Chemistry, School of Science, University of Management and Technology (UMT)) ;
  • Ahmad, Tahir (Atta Ur Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST)) ;
  • Afzal, Muhammad Sohail (Department of Chemistry, School of Science, University of Management and Technology (UMT))
  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Afzal MS, Ahmed T, Zaidi NU. (2014). Comparison of HCV prevalence in Pakistan and Iran; an insight into future. Hepat Mon, 14, 11466
  2. Afzal MS, Anjum S, Zaidi NU. (2013) Effect of functional interleukin-10 polymorphism on pegylated interferon-${\alpha}$ plus ribavirin therapy response in chronic hepatitis c virus patients infected with 3a genotype in Pakistani Population. Hepat Mon, 13, 10274
  3. Afzal MS, Anjum S, Zaidi NU. (2014). Changing of HCV clade pattern in iran; the possible means for something good. Hepat Mon, 14, 11879
  4. Afzal MS, Khan MY, Ammar M et al (2014). Diagnostically untypable hepatitis C virus variants: it is time to resolve the problem. World J Gastroenterol, 20, 17690-2 https://doi.org/10.3748/wjg.v20.i46.17690
  5. Afzal MS, Tahir S, Salman A, et al (2011). Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries, 5, 473-9
  6. Ahmad B, Ali S, Ali I et al (2013). Conventional Interferon Therapy Response among Chronic HCV Patients in Khyber Pakhtunkhwa. J Infect Dis Ther, 1, 104.
  7. Ahmad B, Ali S, Ali I, Azam S, Bashir S (2012). Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK). Virol J, 9, 18. https://doi.org/10.1186/1743-422X-9-18
  8. Akhtar N, Bilal M, Rizwan M. et al (2015). Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district mardan, khyber pakhtunkhawa, Pakistan. Asian Pac J Cancer Prev, 16, 1037-40. https://doi.org/10.7314/APJCP.2015.16.3.1037
  9. Amer S, Hajira A, Muqeetadnan M. (2014). The hepatitis c virus treatment revolution-can thedeveloping world afford it? J GHR, 3, 1131-2.
  10. Anjum S, Afzal MS, Ahmad T, et al (2013). Mutations in the STAT1‑interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy. Mol Med Rep, 8, 487-92
  11. Anjum S, Wahid A, Afzal MS, et al (2013). Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization. J Infect Dis, 208, 1888-97. https://doi.org/10.1093/infdis/jit376
  12. Gane ED. (2014). Hepatitis C beware-the end is nigh. Lancet, 384, 1557-60. https://doi.org/10.1016/S0140-6736(14)61225-3
  13. World health Organization. http://www.who.int/countries/pak/en/ data collected on 07 March 2015.

Cited by

  1. Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan vol.30, pp.4, 2017, https://doi.org/10.1089/vim.2016.0164
  2. Hepatitis C Virus in Pakistan: Community Education Is an Effective Weapon Against the Killer vol.30, pp.8, 2017, https://doi.org/10.1089/vim.2016.0171
  3. Prevalence and Treatment of Untypable HCV Variants in Different Districts of Punjab, Pakistan vol.31, pp.6, 2018, https://doi.org/10.1089/vim.2017.0167